[go: up one dir, main page]

GB2596884A8 - Pharmaceutical composition - Google Patents

Pharmaceutical composition Download PDF

Info

Publication number
GB2596884A8
GB2596884A8 GB2019241.5A GB202019241A GB2596884A8 GB 2596884 A8 GB2596884 A8 GB 2596884A8 GB 202019241 A GB202019241 A GB 202019241A GB 2596884 A8 GB2596884 A8 GB 2596884A8
Authority
GB
United Kingdom
Prior art keywords
composition
5meodmt
inhaler
formulated
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB2019241.5A
Other versions
GB2596884A (en
GB2596884B8 (en
GB202019241D0 (en
GB2596884B (en
Inventor
Feilding-Mellen Cosmo
Mason Timothy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beckley Psytech Ltd
Original Assignee
Beckley Psytech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beckley Psytech Ltd filed Critical Beckley Psytech Ltd
Publication of GB202019241D0 publication Critical patent/GB202019241D0/en
Priority to EP24213283.5A priority Critical patent/EP4483957A3/en
Priority to EP24208163.6A priority patent/EP4595962A3/en
Priority to KR1020237001336A priority patent/KR20230024378A/en
Priority to AU2021289147A priority patent/AU2021289147A1/en
Priority to CA3187020A priority patent/CA3187020A1/en
Priority to CN202411802400.4A priority patent/CN119613319A/en
Priority to DK23157604.2T priority patent/DK4279070T3/en
Priority to FIEP23157604.2T priority patent/FI4279070T3/en
Priority to CN202180055398.7A priority patent/CN116056762B/en
Priority to EP21735379.6A priority patent/EP3941583B9/en
Priority to JP2022576811A priority patent/JP2023530292A/en
Priority to ES23157604T priority patent/ES3007386T3/en
Priority to BR112022025306A priority patent/BR112022025306A2/en
Priority to EP23157604.2A priority patent/EP4279070B1/en
Priority to EP21735380.4A priority patent/EP3941904A1/en
Priority to PCT/GB2021/051475 priority patent/WO2021250434A1/en
Priority to PCT/GB2021/051476 priority patent/WO2021250435A1/en
Priority to IL298871A priority patent/IL298871A/en
Publication of GB2596884A publication Critical patent/GB2596884A/en
Priority to US17/660,873 priority patent/US11518742B2/en
Priority to US17/660,981 priority patent/US11518743B2/en
Priority to US17/817,548 priority patent/US11603353B2/en
Application granted granted Critical
Publication of GB2596884B publication Critical patent/GB2596884B/en
Priority to US17/935,256 priority patent/US11680044B2/en
Priority to US18/162,976 priority patent/US20230348381A1/en
Priority to US18/310,822 priority patent/US20230382858A1/en
Publication of GB2596884B8 publication Critical patent/GB2596884B8/en
Publication of GB2596884A8 publication Critical patent/GB2596884A8/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A composition comprising a pharmaceutically effective amount of a pharmaceutically acceptable benzoate salt of 5-methoxy-N,N-dimethyltryptamine (5MeODMT). The composition may be used as a medicament. The composition may comprise 5MeODMT benzoate at 1.25% concentration. The composition may comprise a dosage amount of 5MeODMT in the range 0.05 – 100 mg. The composition may be formulated for oral, transdermal, inhalable, intravenous, or rectal administration. The composition may be formulated as a tablet, capsule, granules, powder, aerosol, nebulised, vaping, buccal, sublingual, sublabial, injectable, or suppository dosage form. Most preferably, the preparation may be suitable for administration by inhalation, via a dispenser selected from a dry powder inhaler, a nasal inhaler, or a pressurised metered dose inhaler. The composition may comprise one or more pharmaceutically acceptable carriers or excipients, and may comprise one or more of a mucoadhesive enhancer, a penetrating enhancer, cationic polymers, cyclodextrins, Tight Junction Modulators, enzyme inhibitors, surfactants, chelators, and polysaccharides.
GB2019241.5A 2020-06-12 2020-12-07 A pharmaceutical composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine Active GB2596884B8 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
PCT/GB2021/051475 WO2021250434A1 (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
EP21735380.4A EP3941904A1 (en) 2020-06-12 2021-06-14 Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
KR1020237001336A KR20230024378A (en) 2020-06-12 2021-06-14 A composition comprising the benzoate salt of 5-methoxy-N,N-dimethyltryptamine
AU2021289147A AU2021289147A1 (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine
CA3187020A CA3187020A1 (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
CN202411802400.4A CN119613319A (en) 2020-06-12 2021-06-14 Compositions containing benzoate salt of 5-methoxy-N,N-dimethyltryptamine
DK23157604.2T DK4279070T3 (en) 2020-06-12 2021-06-14 COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXY-N,N-DIMETHYLTRYPTAMINE
FIEP23157604.2T FI4279070T3 (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
CN202180055398.7A CN116056762B (en) 2020-06-12 2021-06-14 Compositions containing benzoate salt of 5-methoxy-N,N-dimethyltryptamine
EP21735379.6A EP3941583B9 (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
JP2022576811A JP2023530292A (en) 2020-06-12 2021-06-14 Compositions containing the benzoate salt of 5-methoxy-N,N-dimethyltryptamine
ES23157604T ES3007386T3 (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
BR112022025306A BR112022025306A2 (en) 2020-06-12 2021-06-14 COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXIN, N-DIMETHYLTRIPTAMINE
EP23157604.2A EP4279070B1 (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
EP24213283.5A EP4483957A3 (en) 2020-06-12 2021-06-14 Pharmaceutical composition
PCT/GB2021/051476 WO2021250435A1 (en) 2020-06-12 2021-06-14 Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
EP24208163.6A EP4595962A3 (en) 2020-06-12 2021-06-14 Pharmaceutical composition
IL298871A IL298871A (en) 2020-06-12 2021-06-14 The composition consisting of the benzoate salt of 5-methoxy-N,N-dimethyltryptamine
US17/660,981 US11518743B2 (en) 2020-06-12 2022-04-27 Pharmaceutical composition comprising 5-methoxy-N,N-dimethyltryptamine
US17/660,873 US11518742B2 (en) 2020-06-12 2022-04-27 Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine
US17/817,548 US11603353B2 (en) 2020-06-12 2022-08-04 Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine
US17/935,256 US11680044B2 (en) 2020-06-12 2022-09-26 Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
US18/162,976 US20230348381A1 (en) 2020-06-12 2023-02-01 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
US18/310,822 US20230382858A1 (en) 2020-06-12 2023-05-02 Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2008961.1A GB202008961D0 (en) 2020-06-12 2020-06-12 Pharmaceutical composition

Publications (5)

Publication Number Publication Date
GB202019241D0 GB202019241D0 (en) 2021-01-20
GB2596884A GB2596884A (en) 2022-01-12
GB2596884B GB2596884B (en) 2022-09-21
GB2596884B8 GB2596884B8 (en) 2023-08-09
GB2596884A8 true GB2596884A8 (en) 2023-08-09

Family

ID=71835429

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB2008961.1A Ceased GB202008961D0 (en) 2020-06-12 2020-06-12 Pharmaceutical composition
GB2019241.5A Active GB2596884B8 (en) 2020-06-12 2020-12-07 A pharmaceutical composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB2008961.1A Ceased GB202008961D0 (en) 2020-06-12 2020-06-12 Pharmaceutical composition

Country Status (1)

Country Link
GB (2) GB202008961D0 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
PT3873883T (en) 2019-11-07 2023-03-24 Small Pharma Ltd SYNTHESIS METHOD
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
EP4595962A3 (en) 2020-06-12 2025-10-22 Beckley Psytech Limited Pharmaceutical composition
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2025068714A1 (en) * 2023-09-28 2025-04-03 Beckley Psytech Limited Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1948155T3 (en) * 2006-06-28 2012-10-31 Chelsea Therapeutics Inc Pharmaceutical compositions comprising droxidopa
WO2012173701A1 (en) * 2011-06-16 2012-12-20 President And Fellows Of Harvard College Novel rodent control agents and uses thereof
WO2013063492A1 (en) * 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer

Also Published As

Publication number Publication date
GB202008961D0 (en) 2020-07-29
GB2596884A (en) 2022-01-12
GB2596884B8 (en) 2023-08-09
GB202019241D0 (en) 2021-01-20
GB2596884B (en) 2022-09-21

Similar Documents

Publication Publication Date Title
GB2596884A8 (en) Pharmaceutical composition
FI4279070T3 (en) Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
NZ585856A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
NZ585857A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
JP2009102342A5 (en)
PE20230382A1 (en) NEW PHARMACEUTICAL COMPOSITION FOR DRUG ADMINISTRATION
JP2014515373A5 (en)
RU2010133489A (en) USE OF GAMMA SECRETASE INHIBITORS FOR TREATMENT OF CANCER
TW200500098A (en) Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
SI9200403B (en) New combination of a bronchodilator and a steroidal antiinflammatory drug for treatment of respiratory disorders as well as its use and preparation thereof
EA200802012A1 (en) PHARMACEUTICAL PREPARATIONS IN THE FORM OF SOLUTION FOR DOSING INHALERS UNDER PRESSURE
WO2006058249A3 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
RU2011138490A (en) PHARMACEUTICAL COMPOSITIONS WITH INSTANT EXECUTION CONTAINING OXYCODONE AND NALOXONE
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
JP2020502206A (en) Pharmaceutical dosage forms comprising TASK-1 and TASK-3 channel inhibitors and their use in respiratory disorder therapy
TWI441639B (en) Combination comprising paclitaxel for treating ovarian cancer
CL2024003616A1 (en) Oral pharmaceutical composition and use for the therapy of progressive fibrosing interstitial lung diseases.
RU2011111792A (en) APPLICATION OF PARACETAMOL AND IBUPROFEN IN TREATMENT
SE0401612D0 (en) Inhaling using pods
WO2012075754A1 (en) Pharmaceutical composition for treating acute lymphocytic leukemia
ES2309357T3 (en) NEW SYNERGIC COMBINATION INCLUDING ROFLUMILAST AND FORMOTEROL.
MX2025003202A (en) Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
JP2022019937A (en) Composition for preventing or treating chronic or acute virus infection and/or sepsis in humans or animals
MX384760B (en) A synergic pharmaceutical combination of the active etianomer s-ketorolaco and gabapentin for the treatment of neuropathic pain

Legal Events

Date Code Title Description
S13A Application for inventor to be mentioned (section 13(1)/patents act 1977)

Free format text: APPLICATION FILED; APPLICATION UNDER RULE 10(2) FOR INVENTOR TO BE MENTIONED FILED ON 13 OCTOBER 2022 BY BECKLEY PSYTECH LIMITED

S13A Application for inventor to be mentioned (section 13(1)/patents act 1977)

Free format text: APPLICATION ALLOWED; IN A DECISION OF THE COMPTROLLER DATED 03 AUGUST 2023, THE COMPTROLLER FOUND THAT TIMOTHY MASON SHOULD BE MENTIONED AS A JOINT INVENTOR IN RESPECT OF PUBLISHED PATENT APPLICATION AND GRANTED PATENT GB2596884. THE COMPTROLLER ORDERED THAT AN ADDENDUM SLIP BE PREPARED FOR THE PUBLISHED PATENT APPLICATION AND GRANTED PATENT ACCORDINGLY.